Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials
- 6 July 2023
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (9) , 1199-1212
Abstract
Opinion statement PRCC is a unique histologic entity compared to other forms of renal cell carcinoma, harboring distinct molecular drivers. The WHO 2022 classification is further emphasizing the molecular biology by making molecular classifications of PRCC subclassifications and discontinuing the morphologic type 1 and type 2 classification system. We agree with this functional classification system and encourage all future clinical trials to only include patients with similar diagnosis instead of conducting basket trials (including all nccRCC together) which limits the scientific value of those conclusions. Based on recent disease-specific clinical trial (S1500, PAPMET), the current standard of care for patients with treatment naïve PRCC is cabozantinib. Prospective clinical trials clearly establish that immune checkpoint inhibitor therapy has meaningful activity in PRCC. The data to date include only single-arm clinical trials of combination immune therapy. Despite the positive and encouraging results, we need validation through randomized studies because of the overestimation of effect size seen in single-arm trials. These randomized trials are currently underway and enrolling. We strongly encourage all physicians to support these studies and enroll patients with PRCC to these trials in order to continue improving the standard of care.Keywords
This publication has 58 references indexed in Scilit:
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialThe Lancet Oncology, 2016
- Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaNew England Journal of Medicine, 2016
- Papillary renal cell carcinoma: A review of the current therapeutic landscapeCritical Reviews in Oncology/Hematology, 2015
- Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal DiseaseAmerican Journal of Surgical Pathology, 2015
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)Annals of Oncology, 2015
- Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinomaAnnals of Oncology, 2012
- Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC MarkersAmerican Journal of Surgical Pathology, 2010
- Tubulocystic Carcinoma of the KidneyAmerican Journal of Surgical Pathology, 2009
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell CarcinomaJournal of Clinical Oncology, 2008
- Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer.Gut, 1986